FDA approves new drug to treat Gaucher | The Money Times
Rated • 1 review • health, mental health • themoneytimes.com
Due to the short supply of Cerezyme, the only approved drug for the rare genetic disorder Gaucher, the U.S. Food and Drug Administration (FDA) gave the nod to a new drug Velaglucerase Alfa for injection, (trade name VPRIV), manufactured by Shire Human Genetic Therapies Inc. for pediatric and adult treatment.
Gaucher is a rare disease that afflicts people who are unable to produce sufficient enzyme called glucocerebrosidase.
As a result potentially dangerous amounts of fatty substance, called lipid, builds up in the liver, bones, spleen, bone marrow, and nervous system, which can be hazardous to the health.
VPRIV is an enzyme replacement therapy designed to break down the cerebroside and prevent it from accumulating in patients suffering from the disease.
Gaucher is a rare disease that afflicts people who are unable to produce sufficient enzyme called glucocerebrosidase.
As a result potentially dangerous amounts of fatty substance, called lipid, builds up in the liver, bones, spleen, bone marrow, and nervous system, which can be hazardous to the health.
VPRIV is an enzyme replacement therapy designed to break down the cerebroside and prevent it from accumulating in patients suffering from the disease.
